With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA ...

Conshohocken’s Madrigal inks a $4B-plus global deal to expand its MASH drug pipeline beyond blockbuster Rezdiffra.

A CHEMICAL-FREE alternative to surgical mulesing of sheep is closer with University of Queensland development of technology that improves the efficacy of treatments to hinder and kill blowfly ...

Dublin-based biotech firm Aerska has raised $39m (€33m) in funding to help it advance development of its technology. Aerska is developing medicines that use RNA interference (RNAi), a ...

Irish biotech Aerska raises €32M to deliver RNA medicines to the brain, targeting Alzheimer’s and Parkinson’s at their ...

According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from ...

Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported fourth-quarter net income of $111.5 million, after reporting a loss ...

If you are wondering whether Alnylam Pharmaceuticals at around US$308.48 is still priced sensibly after its run in the biotech space, you are not alone. The stock has seen a 6.9% decline over the last ...

This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial. The results of a clinical trial, called VIBRANT-HD, investigating an oral ...